Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Like this?
Someone needs to sound the bugle and shout out its news as this is a ridiculous rise on a quite brilliant RNS.
Proactive interview with Andrew Newland highlights the work involved
https://www.youtube.com/watch?v=hxu_XmeIpDA
========================
Also very important about the RNS of 4th Jan "Angle PLC Breakthrough clinical results (5877Y)", see link below.:-
Companies doing Cancer drug trials will NOW want standard blood CtDna analysis ***AND*** Circulating Tumour Cell analysis for even more information on how their extremenly expensive drug trials are doing etc. OF COURSE they will want the maximum information available in order to log for the future and evaluate how their drug is performing!!! The IS A NO BRAINER.
And that is just one of Angle's offerings................................................
https://www.lse.co.uk/rns/AGL/breakthrough-clinical-results-b0km788ah9aflqm.html
All IMHO.
Proactive interview with Andrew Newland highlights the work involved
https://www.youtube.com/watch?v=hxu_XmeIpDA
Parsortix still works. It always did...
Huge pat on the back to the scientists at Angle
TwoGood2Die.
Let's discuss given FDA approval for breast cancer testing was granted a while back why global sales of the Parsortix machine hasn't taken off any suggestions?
===================================
How do you know sales of the Parsortix machine @ $50,000 to $70,000 have not taken off. Do we need to add insider trading to the list of illegal things you do? LOL! The results are due. We will see if:-
Companies doing Cancer drug trials NOW want standard blood CtDna analysis ***AND*** Circulating Tumour Cell analysis for even more information on how their extremenly expensive drug trials are doing etc. OF COURSE they will want the maximum information available in order to log for the future and evaluate how their drug is performing!!! The IS A NO BRAINER.
And that is just one of Angle's offerings................................................
TwoGood2Die.
Let's discuss given FDA approval for breast cancer testing was granted a while back why global sales of the Parsortix machine hasn't taken off any suggestions?
===================================
How do you know sales of the Parsortix machine @ $50,000 to $70,000 have not taken off. Do we need to add insider trading to the list of illegal things you do? The bottom line I think you will find is the CtD
EC
Let's discuss given FDA approval for breast cancer testing was granted a while back why global sales of the Parsortix machine hasn't taken off any suggestions?
Copy, copy, copy, paste, paste, paste...same old!
You are the one that does not understand. You are childish and spend most of your sad time trying to annoy people.
I believe the main way of finding the efficacy (effectiveness) of a new cancer treatment drug for people with metastasized cancer (cancer that has spread) used to be to examine them, test them and ask them. Also compare this information with the people that were given the placebo.
Molecular analysis Companies like Illumina and Thermo Fisher now enable the testing of DNA fragments that can be found in blood from a simple blood sample. These fragments are naturally shed by every cell in your body, and that includes the cancerous ones. Analysing the cancerous ones is called CtDna analysis (cancerous tumour Dna analysis). Angle Plc have discovered the following. If you do exactly the same test on a circulating tumour cell taken from the same blood sample and compare it to the so called CtDna analysis results you sometimes get a different result that gives even more information about the state of the persons cancer. Important up to date information. Angle hypothesize this gives "critical new information not currently available on how the cancer is progressing and which therapies may be affective". I think any Company embarking on a cancer drug trial involving a metastasized cancer MUST want this vital new information. It is a "no brainer". It would be criminal not to get this vital information when doing a very expensive cancer drug trial. Criminal IMHO.
All IMHO.
EC
Your just copying and pasting the same stuff over and over again!
You actually don't understand half the timevwgat your actually posting!
Should be a massive winner IMHO. From the RNS dated 4th Jan:-
"ANGLE will start using the clinical results announced today to support the offer of sample-to-answer DNA molecular solutions to pharma services customers using the ****combined CTC-DNA and ctDNA analysis"****.
This will give any cancer drug trial Company ALL THE AVAILABLE INFORMATION about any cancer that has
metastasized (spread). I.e. the DNA analysis of the CtDNA in the general blood (fragments of DNA) combined with the DNA analysis of the Circulating tumour cells (cells that detach from a tumour and can spread a cancer). This sort of information is invaluable to understand how a treatment is performing, or not.
All IMHO.
EC
Desperate times call for desperate measures btw when is the cash placement?
In a tweet about ten minutes ago. I'm not sure what that translates into sales but might give the shares a little boost seeing how low and bombed out there are again
The standard molecular profiling of general blood CtDna (available now using Illumina/Thermo Fisher tech) **AND** circulating tumour cells (CTC's) from the the same blood sample ***for comparison***! See their RNS dated 4th January "Breakthrough clinical results". As pointed out in the RNS, these results meant that it would be in Illumina's etc.. interests to promote the Parsortix machine alongside their standard general blood CtDNA analysis machines to get the "FULL PICTURE". That is using the general blood CtDna and circulating tumour cell CtDNA comparison approach.
Note analysis of the CTC's gave additional sometimes actionable information about the cancer. Actionable in that the standard molecular profiling of general blood CtDna sometimes ***FAILED**** to indicate targetable DNA that ***WAS FOUND*** IN THE circulating tumour cells! Thus, an opportunity to treat the cancer with targeted DNA with immunotherapy could be MISSED!!! I believe Angle were/are open to some sort of deal with the likes of Illumina/Thermo Fisher. We will find out soon I suspect.
However, I had failed to realise that for use in cancer drug trials Angle Plc THEMSELVES can offer this service! They already use Illumina kit for blood CtDNA analysis. It said so in the RNS of 4th Jan (see below). Obviously, they have loads of Parsortix machines their lab to obtain the circulating tumour cells and they have the tech to do the comparison as set out in the RNS!! This offering will be groundbreaking IMHO!!
https://www.lse.co.uk/rns/AGL/breakthrough-clinical-results-b0km788ah9aflqm.html
All IMHO.
Of a cancers status ONLY when BOTH are analysed from the same tube of blood. See RNS dated 4th Jan. This has massive implications for the cancer immunotherapy treatment Companies throughout the World. Angle have pioneered this new approach and are likely to be the ONLY Company in the World to offer this service to Companies carrying out cancer drug trials.............. Soon. Massive potential profits. I bet we get info on this with the results that are due any day.
All IMHO.
You know the one entitled "Breakthrough clinical results"? Comparing the standard blood CtDna analysis currently offered by the likes of Illumina/Thermo Fisher to the analysis of the circulating tumour cells (obtained using Angle's Parsortix machine) from the same tube of blood was interesting, surely? The results indicated in some cases if the circulating tumour cells were not also analysed then important information could be MISSED. I think that is rather important. Do you agree? I don't quite see how you could not agree! Have a think about that one.
EC.
Or maybe these are simply existing jobs and they are recruiting to replace leavers.
"ANGLE has established a CTC harvest and analysis service from our UK-based Clinical Laboratory based in Guildford for customers worldwide. In alignment with company priorities, we plan to rapidly expand our services to include molecular profiling of CTCs and ctDNA using digital PCR and NGS to add to our image-based assays."
TwoGood2Die.
If Angle are doing so badly as you appear to want people to believe then why are they advertising for a purchasing assistant and a Warehouse/Stores operator? Don't tell me...... it's a ruse to improve the sp!! LOL!
Https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0138032
Everyone should give it a rest on umpteen quotes on 'research' use of Parsortix what matters is roll out of Parsortix for actual live 'testing'..
All these copy and paste citing research use are pretty meaningless what matters is commercial sales without which no traction and hence growth will occur.
I'm not saying that 'research' quotes arn't helpful but it's drowning out dialogue on AGL's future commercial prospects because if you can't sell any machines you don't have a future commercial strategy.
As mentioned earlier Parsortix is FDA approved for 'testing' breast cancer do why arn't we seeing any global sales growth in this area for Parsortix sales?
Https://biblio.ugent.be/publication/01HVRMR53RQ0R4Z1PFARV8B9XF
I can't download the whole text. The aim of the research appears to have been to establish methods of increasing further the efficiency of parsortix when dealing with certain types of pancreatic cancer. University of Ghent
Https://www.clinicaltrials.gov/study/NCT05648240?term=parsortix&rank=7